$NFLX - Netflix neared a record all-time high after market close - as the largest streaming service brought in more subscribers than analysts projected in Q3. Profit also beat forecasts, while Revenue was in line with estimates.
EPS of $3.19
Sales +16.3% to $7.48 billion - anticipates another +16% gain in revenue Q4
Profit of $1.4B
Revenue of $7.5B
Netflix...
The electric vehicle maker generated CNY 8.45 billion this quarter, getting closer to break even.
On August 11, 2021, Chinese electric vehicle (EV) maker NIO (NIO:NYSE) released its financial report for the second quarter of 2021, with most key figures improving year on year:
The total revenue hit CNY 8.45 billion, up by 127.2% from Q2 2020 and by 5.8%...
Fair value - $36.... 83% undervalued
cosmetic sales rose 302% YOY
household product sales increased 133% YOY
25.7m cash
25000 stores
2 million VIP members
strong business momentum
strategy execution
unique retail distribution system
gaining customers from many different communities
NASDAQ:COIN could be starting a reversal. The MACD is been going up with the price which today broke above its 50 day MA but it still needs to make the breakout from the $252 resistance. Once that happens could be the start of a good uptrend.
The crypto exchange has had strong revenue and EPS growth, being 2021 its best year. One the first quarter, reported a...
GEORGE TOWN, CAYMAN ISLANDS – May 4, 2021 – Vox Royalty Corp. (TSXV: VOX) (“Vox” or the “Company”) is
pleased to announce that the Company has realized record preliminary revenue of C$668,600 (US$540,000)
(1) for the three-month period ended March 31, 2021. All preliminary revenues were derived from royalties, not streams, as such, the cash operating
margin(1) was...
NASDAQ:NIU has good footprint forming a VCP in the last 13 weeks while above the 200 day moving average. Is not the best type because I like to see this with price also above the 20 and 50 day moving average, but still is worth to look at. Is very possible that a good rally is on the way. Also, the stock has a 92 rating for the IBD Relative Strength; one of the...
SILO has one of the first patent-pending nasal spray making psilocybin easier to access, administer and ingest. They've signed last week a licensing agreement with Brasil and Colombia and expecting now that market penetration in LATAM to continue. This marks the Company’s first commercial transaction of its new-to-world intellectual property and I believe that...
REVENUE
Theme: Payment solution
Rst: 2.30
Spp: 2.23
Still way bullish, only concern is RSI bearish divergence is plaguing the momentum now. If coming candles manage to forge new support above 2.23 area, there’s tendency to see the bearish signal being neutralised
It has already reached 2.275 the target TP for this long. Well, it may go higher.
If tomorrow's candle is a bearish candle then it is possible that it is time for a retracement.
eyes on 0.5% = 2.125 and
eyes on 0.786% = 2.000
We will work it out after it has reached one of those level.
No trades on our side.
All,
Revenue went from 222K to 2.5M Quarter over Quarter. Yes some other fundamentals seem funky, but no uncommon to see bad net income when generating that much revenue at first. If they can sustain that revenue and clean up their margins they are going EXPLODE on options market.
REVENUE
Theme: Payment solution
Rst: 1.90
Spp: 1.82
Violation of candlestick into falling wedge formation again, plus pressure from RSI and MACD second bearish crossover may induce further selling in coming days. Likely to see weakness towards 1.76 area.
I really like the techniclas of NSE:INFY , it has done three breakouts with good volumen and it stayed strong during the market correction. The price is above its key MAs, is in the list of 52-week highs in Barchart and is ranked 4th in its industry by Investors Business Daily with a relative strengh rating of 81.
I mean is almost too perfect to be true so, I...
Some basic chart analysis on Genmab.
This is more to bring your attention to the stocks long term growth prospects.
With a TTM P/E ratio of 29 and a FWD of 3, combined with solid revenue growth TTM and FWD leads me to suggest that Genmab will thrive in the coming months and climb to all time highs.
